Literature DB >> 10573034

Pituitary and extrapituitary actions of gonadotrophin-releasing hormone and its analogues.

O Ortmann1, K Diedrich.   

Abstract

The hypothalamic decapeptide gonadotrophin-releasing hormone (GnRH) binds to high affinity receptors on pituitary gonadotrophs. These receptors mediate the effects of GnRH on secretion and synthesis of gonadotrophins. The GnRH receptor is coupled to Gq/G11, which activates phospholipase C. This enzyme leads to the generation of several second messenger molecules. Among these, diacylglycerol (DG) and inositol 1,4,5-tris-phosphate (IP3) are critically important. DG leads to activation of protein kinase C and IP3 releases Ca2+ from intracellular pools. Both events result in secretion and synthesis of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In addition, other components of the GnRH signal transduction pathway are involved in cellular responses to GnRH. GnRH receptors and their functions are regulated by GnRH itself or other hormones such as ovarian steroids. The prolonged exposure of pituitary gonadotrophs to GnRH leads to desensitization and consequently to suppressed LH and FSH secretion. This mechanism is employed for the clinical use of GnRH agonists. GnRH antagonists act by competitive binding to the pituitary GnRH receptors. Apart from the well-established pituitary actions of GnRH, receptors for the decapeptide have been demonstrated in a variety of extrapituitary tissues. Here we report on the ovarian actions of GnRH which are predominantly inhibitory in the rat ovary. In the human ovary the existence of GnRH receptors is controversial. Recent reports have demonstrated the mRNA for the GnRH receptor in the human ovary. However, to date there is no consensus on the ovarian actions of GnRH or its analogues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10573034     DOI: 10.1093/humrep/14.suppl_1.194

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Promotion of human trophoblasts invasion by gonadotropin-releasing hormone (GnRH) I and GnRH II via distinct signaling pathways.

Authors:  Jing Liu; Colin D Maccalman; Yan-ling Wang; Peter C K Leung
Journal:  Mol Endocrinol       Date:  2009-04-16

2.  Medical Management of Symptomatic Fibroids: Worth It?

Authors:  Chandrashekhar V Hegde
Journal:  J Obstet Gynaecol India       Date:  2017-06-10

Review 3.  Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence.

Authors:  Alice Trefoux Bourdet; Dominique Luton; Martin Koskas
Journal:  Int J Womens Health       Date:  2015-03-26

4.  GnRH antagonist weakens endometrial stromal cells growth ability by decreasing c-kit receptor expression.

Authors:  Ding-Fei Xu; Pei-Pei Liu; Lu Fan; Qi Xie; Zhi-Qin Zhang; Li-Qun Wang; Qiong-Fang Wu; Jun Tan
Journal:  Reprod Biol Endocrinol       Date:  2022-02-04       Impact factor: 5.211

5.  Morphological and enzymatic changes caused by a long-term treatment of female rats with a low dose of gonadoliberin agonist and antagonist.

Authors:  Aleksandra Suszka-Świtek; Piotr Czekaj; Jacek Pająk; Rafał Skowronek; Katarzyna Wrona-Bogus; Danuta Plewka; Danuta Kozłowska-Rup; Ryszard Wiaderkiewicz; Andrzej Jankowski
Journal:  Med Sci Monit       Date:  2012-08

6.  Cessation of gonadotropin-releasing hormone antagonist on triggering day: an alternative method for flexible multiple-dose protocol.

Authors:  Hye Jin Chang; Jung Ryeol Lee; Byung Chul Jee; Chang Suk Suh; Seok Hyun Kim
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

7.  Outcome of cryopreserved-thawed embryo transfer in the GnRH agonist versus antagonist protocol.

Authors:  Maryam Eftekhar; Razieh Dehghani Firouzabadi; Hesamoddin Karimi; Elham Rahmani
Journal:  Iran J Reprod Med       Date:  2012-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.